Clinical Pathway

The Future is Bright for Specialized Phototherapy

Building on over 20 years of research, our proprietary specialized phototherapy technology delivers breakthrough therapeutic benefits for people with Parkinson’s disease.

While previous short-term light therapy trials have demonstrated varying degrees of improvement in motor and non-motor symptoms in Parkinson’s disease, PhotoPharmics supported pilot trials to better understand the effects of various wavelengths, intensities, and session frequency of light administration. Click here for a complete list of referenced articles.

Our research yielded a light administration protocol and a combination of intensities and wavelengths now embodied in our specialized light therapy medical device called Celeste®. Placed at arm’s length and bathing the user’s face in light, this treatment is both convenient and non-invasive and promises to be effective in improving motor and non-motor function and quality of life for people with Parkinson’s disease and promises improvement in other neurodegenerative diseases.

Physiological Evidence

(referenced articles)

Clinical Trials

Completed 92 Patient Trial

Patients showed dramatic improvement in our proof-of-concept, multi-national, randomized, double-blind, controlled trial. The trial involved 92 patients to assess the safety and efficacy of our specialized phototherapy, non-drug treatment for motor and non-motor symptoms in Parkinson’s disease. Learn more at clinicaltrials.gov (#NCT02175472).

  • Safety. As anticipated, no specific serious adverse events were reported in the trial. Patients experienced only benign and transitory side effects.
  • Efficacy. We saw clinically meaningful improvements in combined both motor and non-motor function, on top of best medical care, and they enjoyed improved quality of life. Preliminary trial results can be viewed here.

NEW! Upcoming Pivotal Trial

PhotoPharmics is steadily moving specialized phototherapy forward to become a standard of care in Parkinson’s disease. PhotoPharmics announced a 300-patient pivotal trial to establish the efficacy of the next generation of our specialized phototherapy treatment.

Read our recent announcement here. Additional details are available at www.clinicaltrials.gov (#NCT04453033). If you or someone you know would like to be considered for this trial, click here.

Mechanism of Action

Improving Circadian Function

Circadian rhythms are the daily biological cycles that regulate physical, mental and behavioral function. Special photoreceptors in our eyes use light to regulate these rhythms. These photoreceptors respond to a specific bandwidth or color and intensity of light.

These photoreceptors are damaged in Parkinson’s, and as a result, Parkinson’s circadian rhythms are severely blunted, causing reduced energy, mood, and activity during the day, with poor sleep at night.  PD medications cause these rhythms to run faster than normal, which can make one feel even more fatigued earlier in the afternoon and evening, and experience even more sleep problems.

Our specialized phototherapy targets these photoreceptors with a specific bandwidth of therapeutic light to allow these photoreceptors to start signaling again.  By addressing circadian dysregulation in PD, this therapy may improve motor and non-motor function and help PD patients enjoy greater quality of life.

Circadian dysfunction is a hallmark several neurodegenerative diseases, including Alzheimer’s, Huntington’s and Parkinson’s. 

The Cycle of Innovation, Clinical Research, and Improved Lives

For decades our founders innovated treatments of specialized light therapy in circadian-related neuropsychiatric disorders. They researched the new product’s safety and efficacy and delivered those innovations to and blessed the lives of hundreds of thousands of patients.

The founders of PhotoPharmics have applied their expertise to circadian dysregulation in neurodegenerative disease. This resulted in a new platform technology which was adapted into a safe and convenient product for Parkinson’s patients. PhotoPharmics is currently validating this product in robust clinical research. With demonstrated safety and efficacy, we anticipate these products will become widely available for people with Parkinson’s.

In addition to improving the lives of Parkinson’s patients we have reason to believe that specialized phototherapy can contribute to the treatment of other neurodegenerative diseases. PhotoPharmics is now applying what we’ve learned in Parkinson’s into new products and additional disease states. We will look to validate those products in robust clinical research, and if successful, get the solutions into the hands of individuals who suffer from these neurodegenerative diseases.

Working Together

Join us in improving lives by supporting our innovation and participating in our clinical research.